NanoViricides, Inc.

NYSE American NNVC

NanoViricides, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024: USD -569.89 K

NanoViricides, Inc. Gross Profit is USD -569.89 K for the Trailing 12 Months (TTM) ending September 30, 2024, a 24.34% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

NanoViricides, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -753.25 K, a -3.14% change year over year.
NanoViricides, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -730.30 K, a -38.12% change year over year.
NanoViricides, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -528.73 K, a 0.00% change year over year.
NanoViricides, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 0.00, a 0.00% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NYSE American: NNVC

NanoViricides, Inc.

CEO	Dr. Anil R. Diwan Ph.D.
IPO Date	Oct. 26, 2005
Location	United States
Headquarters	1 Controls Drive
Employees	7
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

Key trends

Past 5 years